Abstract OT-09-11: AMEERA-4, a phase 2 window study of SAR439859 vs letrozole in post-menopausal women with newly diagnosed estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer

Growth Factor Receptor ◽

Phase 2 ◽

Newly Diagnosed ◽

Her2 Breast Cancer ◽

Menopausal Women ◽

Epidermal Growth ◽

Abstract P4-15-10: Initial therapy among patients newly diagnosed with operable early stage human epidermal growth factor receptor 2-overexpressed (HER2+) breast cancer in the US: A real-world retrospective study

10.1158/1538-7445.sabcs14-p4-15-10 ◽

2015 ◽

Author(s):

Stacey DaCosta Byfield ◽

Philip O Buck ◽

Cori Blauer-Peterson ◽

Sara A Poston

Keyword(s):

Breast Cancer ◽

Retrospective Study ◽

Early Stage ◽

Growth Factor Receptor ◽

Initial Therapy ◽

Newly Diagnosed ◽

Her2 Breast Cancer ◽

The Us ◽

Randomized phase 2 neoadjuvant trial evaluating anastrozole and fulvestrant efficacy for postmenopausal, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients: Results of the UNICANCER CARMINA 02 French trial

Cancer ◽

10.1002/cncr.30143 ◽

2016 ◽

Vol 122 (19) ◽

pp. 3032-3040 ◽

Cited By ~ 11

Author(s):

Florence Lerebours ◽

Sofia Rivera ◽

Marie-Ange Mouret-Reynier ◽

Severine Alran ◽

Laurence Venat-Bouvet ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Growth Factor Receptor ◽

Phase 2 ◽

Breast Cancer Patients ◽

Postmenopausal Estrogen ◽

Epidermal Growth ◽

Randomized Phase 2

PCN246 BUDGET IMPACT OF RIBOCICLIB PLUS LETROZOLE FOR THE TREATMENT OF POST-MENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE (HR+), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2- NEGATIVE (HER2-) ADVANCED OR METASTATIC BREAST CANCER IN DENMARK

Value in Health ◽

10.1016/j.jval.2019.09.441 ◽

2019 ◽

Vol 22 ◽

pp. S483

Author(s):

A.H. Møller ◽

L. Oddershede

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Budget Impact ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Hormone Receptor Positive ◽

Menopausal Women ◽

Epidermal Growth ◽

Everolimus (EVE) + exemestane (EXE) vs EVE alone or capecitabine (CAP) for estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): BOLERO-6, an open-label phase 2 study.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.1005 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 1005-1005 ◽

Cited By ~ 1

Author(s):

Guy Heinrich Maria Jerusalem ◽

Elena Kovalenko ◽

Denise A. Yardley ◽

Richard H. De Boer ◽

Sara A. Hurvitz ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Growth Factor Receptor ◽

Phase 2 ◽

Open Label ◽

Phase 2 Study ◽

Open Label Phase ◽

Healthcare medical costs among post-menopausal women with hormone receptor positive and human epidermal growth factor receptor 2 negative (HR+/HER2-) metastatic breast cancer (mBC) managed with systemic therapy following CDK 4/6 inhibitor (CDKi) in the real-world setting.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.1067 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 1067-1067

Author(s):

Nicole Princic ◽

Derek Tang ◽

Aditya Bardia ◽

David Smith ◽

William M. Johnson ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Hormone Receptor Positive ◽

Real World Setting ◽

Menopausal Women ◽

Epidermal Growth ◽

KEYNOTE-756: Randomized, double-blind, phase III study of pembrolizumab vs placebo + neoadjuvant chemotherapy (CT) and adjuvant endocrine therapy (ET) for high-risk, early-stage estrogen receptor–positive human epidermal growth factor receptor 2–negative (ER+/HER2−) breast cancer (BC)

Annals of Oncology ◽

10.1093/annonc/mdz097.013 ◽

2019 ◽

Vol 30 ◽

pp. iii38 ◽

Cited By ~ 1

Author(s):

F. Cardoso ◽

L. Jia ◽

K. Hirshfield ◽

V. Karantza

Keyword(s):

Breast Cancer ◽

Early Stage ◽

Growth Factor Receptor ◽

Phase Iii ◽

Double Blind ◽

Her2 Breast Cancer ◽

Phase Iii Study ◽

PO56 BOLERO-4: A PHASE 2, OPEN-LABEL, MULTICENTER, SINGLE-ARM TRIAL INVESTIGATING THE EFFICACY AND SAFETY OF FIRST-LINE EVEROLIMUS (EVE) IN COMBINATION WITH LETROZOLE (LET) IN POSTMENOPAUSAL PATIENTS (PTS) WITH ESTROGEN RECEPTOR–POSITIVE (ER+), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2–NEGATIVE (HER2–) METASTATIC OR LOCALLY ADVANCED UNRESECTABLE BREAST CANCER (BC)

The Breast ◽

10.1016/s0960-9776(15)30068-0 ◽

2015 ◽

Vol 24 ◽

pp. S41

Author(s):

Thomas Bachelot ◽

Cristian Villanueva ◽

Melanie Royce ◽

Marc Debled ◽

Felipe Melo Cruz ◽

...

Keyword(s):

Breast Cancer ◽

Locally Advanced ◽

Growth Factor Receptor ◽

Phase 2 ◽

Efficacy And Safety ◽

First Line ◽

Open Label ◽

Abstract OT-09-09: AMEERA-3, a phase 2 trial of SAR439859 vs endocrine monotherapy in pre- and post-menopausal, estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (her2−), locally advanced or metastatic breast cancer (BC) with prior exposure to hormonal therapies

10.1158/1538-7445.sabcs20-ot-09-09 ◽

2021 ◽

Author(s):

Sara Tolaney ◽

Irfan Cicin ◽

Rafael Betancourt ◽

Arlene Chan ◽

Diego Kaen ◽

...

Keyword(s):

Breast Cancer ◽

Locally Advanced ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Phase 2 ◽

Phase 2 Trial ◽

Epidermal Growth ◽

Hormonal Therapies ◽

Everolimus use and associated factors among post-menopausal women with hormonal receptor positive/human epidermal growth factor receptor 2 negative metastatic breast cancer

Current Medical Research and Opinion ◽

10.1185/03007995.2015.1062358 ◽

2015 ◽

Vol 31 (8) ◽

pp. 1573-1582 ◽

Cited By ~ 3

Author(s):

Nanxin Li ◽

Yanni Hao ◽

Jipan Xie ◽

Peggy L. Lin ◽

Zhou Zhou ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Growth Factor ◽

Associated Factors ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Menopausal Women ◽

Epidermal Growth ◽

BOLERO-4: Phase 2 trial of first-line everolimus (EVE) plus letrozole (LET) in estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2-) advanced breast cancer (BC)

Annals of Oncology ◽

10.1093/annonc/mdw365.01 ◽

2016 ◽

Vol 27 ◽

pp. vi68 ◽

Cited By ~ 5

Author(s):

M. Royce ◽

C. Villanueva ◽

M. Ozguroglu ◽

T. Bachelot ◽

S. Azevedo ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Growth Factor ◽

Growth Factor Receptor ◽

Phase 2 ◽

First Line ◽

Phase 2 Trial ◽